logo
科言猫学术研究的AI总结
language
手机端手机端
  • Phone Feature微信小程序
简体中文简体中文
notice消息通知
博客博客
arrow
返回期刊详情
Therapeutic Advances in Drug Safety 封面图

Therapeutic Advances in Drug Safety

IF3.4
论文数465
被引数1675
期刊论文 465
发表时间
delete
Medication knowledge in psychiatric day hospital patients: The role of polypharmacy精神科日间病房患者的药物知识：联合用药的作用
deleteTherapeutic Advances in Drug Safety
IF3.4
delete2026-10-28
delete0
PREAI
deleteLina Sophia Queck; Johannes Heck; Olaf Krause; Martin Klietz; Franziska Kümpers; Ricarda-Katharina Vagi; Adrian Groh; Martin Schulze Westhoff; Sebastian Schröder
delete分享
delete收藏
Using a control plan for artificial intelligence and machine learning monitoring within pharmacovigilance利用控制计划进行人工智能和机器学习在药物警戒中的监控
deleteTherapeutic Advances in Drug Safety
IF3.4
delete2026-10-21
delete0
PREAI
deleteMichael Glaser; Rory Littlebury; Vijay Kara
delete分享
delete收藏
Specialist teleconsultation and changes in potentially inappropriate medication regimens among older adults in primary care: The AMELIORATION retrospective cohort study专科远程会诊与初级保健中老年人潜在不适当用药方案的变化：AMELIORATION回顾性队列研究
deleteTherapeutic Advances in Drug Safety
IF3.4
delete2026-10-21
delete0
PREAI
deleteTarso Augusto Duenhas Accorsi; Juan Manuel São Bento Batista; Carlos Francisco da Silva; Flavia Oliveira Rodrigues; Anderson Aires Eduardo; Flavio Tocci Moreira; Karen Francine Köhler; Carlos Henrique Sartorato Pedrotti
delete分享
delete收藏
Multisystem adverse drug events of low-dose tirzepatide in a normal - Weight individual: A case report and literature review低剂量替尔泊肽的多系统不良反应：1例病例报告及文献综述
deleteTherapeutic Advances in Drug Safety
IF3.4
delete2026-10-03
delete0
PREAI
deleteMeixia Li; Congkai Zhou; Jinggang Zhou
delete分享
delete收藏
Comparative pharmacovigilance of glycaemic adverse-event reporting for alpelisib and capivasertib: A disproportionality analysis of the FDA adverse event monitoring system阿培利司和卡匹巴斯替韦血糖不良事件报告的药物警戒比较：FDA不良事件监测系统的差异分析
deleteTherapeutic Advances in Drug Safety
IF3.4
delete2026-09-30
delete0
PREAI
deleteYongjian Liu; Hao Zhong; Xingjun Huang; Yige Yu; Shuzhen Liu; Yingyu Yu
delete分享
delete收藏
Risk of Clostridioides difficile infection with potassium-competitive acid blockers: A systematic review with restricted quantitative synthesis钾竞争性酸阻滞剂导致艰难梭菌感染的风险：一项受限定量合成的系统评价
deleteTherapeutic Advances in Drug Safety
IF3.4
delete2026-09-28
delete0
PREAI
deleteAh Young Lee; Kwanjoo Lee; Sun Jae Moon; Seung-Hun You; Jun-young Seo; Wonsuk Shin
delete分享
delete收藏
Comment on “Machine learning studies of drug-induced nephrotoxicity: A scoping review”. The missing role of causality对“药物诱导肾毒性的机器学习研究：一项范围综述”的评论。因果关系的缺失角色
deleteTherapeutic Advances in Drug Safety
IF3.4
delete2026-09-24
delete0
PREAI
deleteIzak A. R. Yasrebi-de Kom; Joanna E. Klopotowska
delete分享
delete收藏
Safety-guided selection of CDK4/6 inhibitors in HR+/HER2− metastatic breast cancer: toxicity profiles, dose modification, and clinical risk–benefit considerationsCDK4/6抑制剂在HR+/HER2−转移性乳腺癌中的安全性指导选择：毒性特征、剂量调整及临床风险效益考量
deleteTherapeutic Advances in Drug Safety
IF3.4
delete2026-09-16
delete0
PREAI
deleteNidhi Shrivastava; Santosh Laxman Gaonkar; Fayaz Shaik Mahammad
delete分享
delete收藏
Transient monocular vertical hemifield loss as a rare acute oxaliplatin-induced ophthalmological side effect: a case report and review of the literature短暂性单眼垂直半视野缺失作为罕见的急性奥沙利铂诱导的眼科副作用：病例报告及文献综述
deleteTherapeutic Advances in Drug Safety
IF3.4
delete2026-09-01
delete0
PREAI
deleteLucie Regaldo-Saint Blancard; Simon Pernot; Marianne Fonck; Lola Jade Palmieri
delete分享
delete收藏
Evaluation of digoxin dosing and therapeutic drug monitoring in adult patients receiving continuous venovenous hemodiafiltration评估接受连续静脉-静脉血液透析滤过治疗的成年患者中地高辛的剂量和药物浓度监测
deleteTherapeutic Advances in Drug Safety
IF3.4
delete2026-09-01
delete0
PREAI
deleteMadison P. Nordin; Jenna F. Cox; Bryan L. Love; Breanne Mefford
delete分享
delete收藏
An assessment of medication errors and associated factors to strengthen patient safety practices in a tertiary hospital in Cameroon对喀麦隆一家三级医院中药物错误及其相关因素的评估，以加强患者安全实践
deleteTherapeutic Advances in Drug Safety
IF3.4
delete2026-08-21
delete0
PREAI
deleteAlberic Ndonku Signang; Mbohjim Othniel Mobit; Taneh Yvonne Shee; Jaques Van Heerden
delete分享
delete收藏
Factors associated with medication administration errors in hospitalized pediatric patients: A scoping review住院儿科患者用药错误的相关因素：一项范围综述
deleteTherapeutic Advances in Drug Safety
IF3.4
delete2026-08-21
delete0
PREAI
deleteClaudia Lorena Motta Robayo; Jonathan Martínez Pinto; Bryan Tabango Goyes; Laura Varela Chagüendo; Eduardo Duque Grisales; Ricardo Ballesteros-Ramírez
delete分享
delete收藏
Post-marketing safety signals and report-level ARIA-E stratification for lecanemab and donanemab: an integrated FAERS and WHO-VigiAccess pharmacovigilance study上市后安全性信号及病例报告级别的ARIA-E分层分析：一项整合FAERS和WHO-VigiAccess的药物警戒研究
deleteTherapeutic Advances in Drug Safety
IF3.4
delete2026-08-18
delete0
PREAI
deleteWei-Yang Xue; Xi Li; Wen-Ting Li; Bao-Zhi Qin; Cong-Zhi Wang; Tao Liu; Min Wang
delete分享
delete收藏
Development and validation of a MedDRA-based signal detection construct for drug-induced neurobehavioral impairment基于MedDRA的药物诱导神经行为损伤信号检测结构的开发与验证
deleteTherapeutic Advances in Drug Safety
IF3.4
delete2026-08-03
delete0
PREAI
deleteChristopher D. Breder
delete分享
delete收藏
Disproportionality analysis of off-label intravitreal bevacizumab in the FDA Adverse Event Reporting System databaseFDA不良事件报告系统数据库中标签外玻璃体内注射贝伐珠单抗的不成比例性分析
deleteTherapeutic Advances in Drug Safety
IF3.4
delete2026-07-28
delete0
PREAI
deleteHomero Contreras-Salinas; Janet Cristina Vázquez-Beltrán; Gisela García-Sánchez; Sebastian Quirarte-Justo; Sarahí del Carmen Gómez-Macías; Lourdes Yolotzin Rodríguez-Herrera
delete分享
delete收藏
Development and prospective validation of a machine learning model for risk stratification of drug-induced liver injury using real-world clinical data基于真实世界临床数据开发并前瞻性验证用于药物性肝损伤风险分层的机器学习模型
deleteTherapeutic Advances in Drug Safety
IF3.4
delete2026-07-25
delete0
PREAI
deleteNgan Thi Tran; Tung My Pham; Mai Thi Quynh Ngo; Anh Van Tran; Thu Thi Kim Ninh; Long Duc Nguyen; Dung Van Hoang; Phuong Thi Thu Nguyen
delete分享
delete收藏
Sex-specific risk factors for genital infections associated with SGLT2 inhibitors in type 2 diabetes: a retrospective cohort study and disproportionality analysis using JADER2型糖尿病中与SGLT2抑制剂相关的生殖器感染性别特异性危险因素：一项基于JADER的回顾性队列研究和不成比例性分析
deleteTherapeutic Advances in Drug Safety
IF3.4
delete2026-07-20
delete0
PREAI
deleteAyami Kajiwara-Morita; Sawa Kugimoto; Kentaro Oniki; Akira Yoshida; Noboru Kurinami; Tomoko Suzuki; Fumio Miyamoto; Kunio Hieshima; Seigo Sugiyama; Keizo Kajiwara; Katsunori Jinnouchi; Hideaki Jinnouchi; Junji Saruwatari
delete分享
delete收藏
Prolonged neonatal phosphate retention and transient hypercalcemia following antenatal Burosumab exposure: a pharmacovigilance alert新生儿期磷酸盐潴留延长及产前Burosumab暴露后一过性高钙血症：一则药物警戒警报
deleteTherapeutic Advances in Drug Safety
IF3.4
delete2026-07-12
delete0
PREAI
deleteGuido Filler; Funmbi Babalola; Andrea Cowan; Tayyab Khan; Leanne Ward
delete分享
delete收藏
Team approach to polypharmacy evaluation and reduction for general practice patients with dementia: the Australian TAPERDem study针对痴呆症一般实践患者的多药治疗评估与减少的团队方法：澳大利亚TAPERDem研究
deleteTherapeutic Advances in Drug Safety
IF3.4
delete2026-07-10
delete0
PREAI
deleteChristopher Etherton-Beer; Amy Theresa Page; Hui Wen Quek; Lynne Parkinson; Vasi Naganathan; Gillian Caughey; Julie Redfern; Rhonda Clifford; Sarah Hilmer; Dee Mangin
delete分享
delete收藏
Sequential analysis for post-marketing drug safety surveillance using routinely collected electronic healthcare data: a scoping review利用常规收集的电子医疗数据对上市后药物安全性监测进行序贯分析的综述
deleteTherapeutic Advances in Drug Safety
IF3.4
delete2026-07-07
delete0
PREAI
deleteYixin Sun; Qian Ding; Hongting Nie; Peng Guo
delete分享
delete收藏